Get to know our clinical trials
Randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
EL OBJETIVO PRINCIPAL DE ESTE ESTUDIO ES SABER SI EL VEREKITUG ES CAPAZ DE MEJORAR LA EPOC Y SUS EFECTOS SOBRE LA SALUD, PARA LO QUE LO VA A COMPARAR CON UN PLACEBO. UN PLACEBO ES UN PRODUCTO QUE TIENE EL MISMO ASPECTO QUE EL VEREKITUG, PERO NO CONTIENE MEDICAMENTO ACTIVO. EN ADELANTE EN ESTE DOCUMENTO, EL VEREKITUG Y EL PLACEBO SE DENOMINAN ¿FÁRMACO DEL ESTUDIO¿
Technical Summary
- PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEREKITUG (UPB-101) IN PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).
- Code EudraCT: 2025-520488-42-00
- Protocol number: UPB-CP-06
- Promoter: UPSTREAM INC
- Molecule/Drug: UPB-101
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.